TSE:GEN GeneNews (GEN) Stock Price, News & Analysis → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free GEN Stock Alerts Add Compare Share Share Today's Range N/A50-Day RangeC$0.15▼C$0.1552-Week Range N/AVolume473,147 shsAverage Volume1.48 million shsMarket CapitalizationC$25.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get GeneNews alerts: Email Address Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About GeneNews Stock (TSE:GEN)GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is headquartered in Richmond Hill, Canada.Read More Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! GEN Stock News HeadlinesJanuary 18, 2024 | msn.comVertex, Crispr Get Second FDA Approval for Gene TherapyJanuary 17, 2024 | msn.comGene-editing treatment from Vertex and CRISPR cleared for second rare blood disorderApril 24, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.January 17, 2024 | msn.comFDA expands use of newly approved CRISPR therapyJanuary 16, 2024 | washingtonpost.comOhio St hires Texas A&M athletic director Ross Bjork to replace the retiring Gene SmithNovember 27, 2023 | msn.comMutated gene thought to exist in just 4% of people could ‘help tackle obesity’November 18, 2023 | nytimes.comSickle-Cell Treatment Created With Gene Editing Wins U.K. ApprovalNovember 17, 2023 | msn.comUK authorizes gene therapy for blood disorders in world firstApril 24, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.November 16, 2023 | msn.comMac Jones Losing Support of Patriots Teammates After Being Benched for Third Time, ReportNovember 16, 2023 | usatoday.comGene Frenette: Mac Jones' decline with Patriots also a product of Bill Belichick negligenceOctober 31, 2023 | msn.comSarepta Seeks Broader Approval for Gene Therapy Even After Drug Trial FizzledOctober 31, 2023 | wsj.comSarepta Therapeutics Stock Dives After New Gene Therapy DataOctober 31, 2023 | msn.comFDA panel considers gene therapy as a potential cure for the sickest sickle cell patientsMarch 27, 2023 | marketwatch.comOncology Molecular Diagnostics Market by 2031March 19, 2023 | marketwatch.comGlobal Colorectal Cancer Diagnostic Market Industry Insights, Drivers, Top Trends, Global Analysis, Forecast and Opportunities to 2030 By VMReportsJanuary 5, 2023 | thestreet.comBiotech Stock Mailbag: GenVecFebruary 23, 2022 | investing.comStageZero Life Sciences Ltd (SZLS)See More Headlines Receive GEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeneNews and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolTSE:GEN CUSIPN/A CIKN/A Webwww.genenews.com Phone+1-905-7392030FaxN/AEmployees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.10 Quick Ratio0.05 Sales & Book Value Annual SalesC$234,592.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow145.00 Book ValueC($0.06) per share Price / BookN/AMiscellaneous Outstanding Shares169,963,000Free FloatN/AMarket CapC$25.49 million OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. James R. Howard-TrippExec. Chairman & CEOMs. Joanna M. Halsey Esq.Gen. Counsel, Chief Compliance Officer & HR Director of IDLProf. Choong-Chin Liew Ph.D.Co-FounderMr. Warren Whitehead (Age 67)Chief Accountant Mr. David SuriaSr. ScientistKey CompetitorsLED Medical DiagnosticsCVE:LMDLexaGeneCVE:LXGAkuminTSE:AKUAcasti PharmaCVE:ACSTCloudMD Software & ServicesCVE:DOCView All Competitors GEN Stock Analysis - Frequently Asked Questions What other stocks do shareholders of GeneNews own? Based on aggregate information from My MarketBeat watchlists, some companies that other GeneNews investors own include StorageVault Canada (SVI), American Airlines Group (AAL), Aareal Bank (ARL), Broadcom (AVGO), Aspen Technology (AZPN), British American Tobacco (BATS), Cronos Group (CRON) and Edwards Lifesciences (EW). How do I buy shares of GeneNews? Shares of GEN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:GEN) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss RatingsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneNews Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
